Multiple sclerosis is one of the most common causes of neurological disability among young adults worldwide. The disease is characterized by autoimmune-mediated destruction of myelin, neuroaxonal degeneration, gliosis, and progressive neurological dysfunction. Clinical manifestations vary considerably and include motor impairment, sensory disturbances, visual deficits, fatigue, and cognitive dysfunction.

Magnetic resonance imaging has revolutionized the diagnosis and monitoring of MS. Conventional MRI sequences, including T1-weighted, T2-weighted, and fluid-attenuated inversion recovery (FLAIR) imaging, are highly sensitive for lesion detection. However, lesion number and volume frequently correlate poorly with clinical disability, resulting in the clinico-radiological paradox.

Recent advances in MRI technology have enabled quantitative assessment of tissue integrity, microstructural damage, neurochemical alterations, iron deposition, and functional network reorganization. These advanced imaging modalities provide insights into pathological mechanisms that remain invisible on conventional imaging.

This review summarizes the role of advanced MRI techniques as biomarkers of disease progression and disability in multiple sclerosis.

Magnetization Transfer Imaging

Magnetization transfer imaging evaluates interactions between free water protons and macromolecule-bound protons within tissues. The principal quantitative parameter derived from MTI is the magnetization transfer ratio (MTR).

Numerous studies have demonstrated reduced MTR values within MS lesions, normal-appearing white matter, and gray matter. These reductions reflect myelin loss, axonal injury, and tissue destruction. Importantly, MTR abnormalities can be detected even in regions that appear normal on conventional MRI.

Several investigations have reported significant correlations between lower MTR values and higher Expanded Disability Status Scale (EDSS) scores. Therefore, MTI may provide a sensitive marker of diffuse pathological changes and disease progression.

Diffusion Tensor Imaging

Diffusion tensor imaging quantifies the directional movement of water molecules within biological tissues. Key DTI parameters include fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD).

Reduced FA and elevated diffusivity metrics are consistently observed in MS lesions and normal-appearing white matter. These findings reflect disruption of axonal integrity and demyelination.

DTI abnormalities frequently correlate with physical disability, cognitive impairment, and disease duration. Tract-specific analyses have revealed significant involvement of the corticospinal tracts, corpus callosum, and cerebellar pathways, highlighting the widespread nature of microstructural damage in MS.

Magnetic Resonance Spectroscopy

Magnetic resonance spectroscopy provides non-invasive measurement of tissue metabolites.

The most extensively studied metabolite in MS is N-acetylaspartate (NAA), a marker of neuronal integrity. Reduced NAA concentrations have been documented in both lesions and normal-appearing brain tissue, suggesting widespread neuroaxonal dysfunction.

Elevated choline levels reflect increased membrane turnover and inflammatory activity, while alterations in creatine and myoinositol provide additional information regarding cellular metabolism and gliosis.

Longitudinal studies indicate that reductions in NAA may precede irreversible neurological deterioration, making MRS a potentially valuable biomarker for disease progression.

Quantitative Susceptibility Mapping

Quantitative susceptibility mapping is an emerging technique that enables visualization and quantification of magnetic susceptibility sources within tissues, particularly iron.

Abnormal iron accumulation has been observed in deep gray matter structures including the thalamus, putamen, caudate nucleus, and globus pallidus. Iron deposition is believed to contribute to oxidative stress and neurodegeneration.

Studies have demonstrated associations between increased susceptibility values, disease duration, brain atrophy, and disability progression. These findings suggest that QSM may serve as a marker of chronic neurodegenerative processes in MS.

Functional MRI

Functional MRI evaluates brain activity through blood oxygen level-dependent (BOLD) signal changes.

Resting-state fMRI studies have identified widespread alterations in functional connectivity within motor, cognitive, and default mode networks. Early stages of disease often demonstrate increased connectivity, which may represent compensatory neural reorganization.

As disease progresses, compensatory mechanisms appear to fail, resulting in reduced connectivity and network fragmentation. Functional abnormalities correlate with cognitive impairment, fatigue, and physical disability.

Task-based fMRI studies further demonstrate altered cortical activation patterns during motor and cognitive tasks, reflecting adaptive and maladaptive neuroplasticity.

Clinical Implications

Advanced MRI techniques offer several advantages over conventional imaging. They provide quantitative biomarkers that reflect specific pathological processes, including demyelination, axonal injury, neuronal loss, iron accumulation, and network dysfunction.

These biomarkers may facilitate earlier detection of disease progression, improve patient stratification in clinical trials, and enhance monitoring of therapeutic responses. Integration of multiple imaging modalities may provide a more comprehensive understanding of disease activity than any single technique alone.

Limitations

Despite promising findings, several limitations remain. Variability in MRI acquisition protocols, image processing methods, field strengths, and analytical approaches complicates comparison across studies. Many investigations are cross-sectional and involve relatively small sample sizes. Standardization and multicenter validation are required before widespread clinical

implementation.

The present review highlights the growing role of advanced MRI techniques as biomarkers of disease progression in multiple sclerosis. While conventional MRI remains indispensable for diagnosis and monitoring inflammatory lesion activity, its ability to predict clinical disability is limited. Advanced MRI modalities provide quantitative measures that better reflect the underlying pathological mechanisms responsible for neurological deterioration.

One of the principal findings of this review is that magnetization transfer imaging demonstrates consistent sensitivity to demyelination and tissue destruction. Reductions in magnetization transfer ratio have been observed not only within visible lesions but also in normal-appearing white matter and gray matter. These findings support the concept that MS is a diffuse disease involving widespread tissue damage beyond focal plaques. The association between lower MTR values and higher disability scores further emphasizes the clinical relevance of MTI as a marker of disease burden.

Diffusion tensor imaging similarly provides valuable information regarding microstructural integrity. Alterations in fractional anisotropy and diffusivity parameters indicate disruption of axonal architecture and myelin integrity. Importantly, DTI abnormalities are frequently detected in tissue that appears normal on conventional MRI, suggesting that microstructural injury begins before visible lesion formation. Associations between DTI metrics and motor, cognitive, and functional impairment suggest that diffusion-based biomarkers may be useful indicators of disease progression and treatment response.

Magnetic resonance spectroscopy offers unique insights into the biochemical consequences of MS. Reductions in N-acetylaspartate consistently indicate neuronal dysfunction and axonal loss, whereas elevated choline levels reflect inflammatory activity and membrane turnover. The ability of MRS to detect metabolic abnormalities before irreversible tissue loss occurs may provide opportunities for earlier therapeutic intervention. Furthermore, longitudinal studies suggest that metabolite changes may predict future disability accumulation.

Quantitative susceptibility mapping has emerged as an important technique for investigating iron-related neurodegeneration. Excessive iron deposition within deep gray matter structures has been linked to oxidative stress, mitochondrial dysfunction, and chronic neurodegeneration. The observed associations between increased susceptibility values, disease duration, brain atrophy, and disability support the hypothesis that iron accumulation contributes to progressive neurological decline. As QSM technology continues to evolve, it may become an important tool for identifying patients at risk of progressive disease.

Functional MRI contributes a different perspective by evaluating alterations in neural network activity. Early increases in functional connectivity likely represent compensatory mechanisms aimed at preserving neurological function despite structural damage. However, progressive loss of connectivity and network organization in advanced disease suggests failure of these compensatory processes. These findings highlight the dynamic nature of neuroplasticity in MS and demonstrate how functional alterations may precede overt clinical deterioration.

Collectively, the evidence reviewed indicates that advanced MRI biomarkers provide substantially greater insight into disease pathology than lesion counts alone. The combination of structural, metabolic, susceptibility-based, and functional imaging allows a multidimensional assessment of disease activity. Such an approach may improve prediction of disease progression, facilitate patient stratification, and enhance evaluation of therapeutic efficacy in both clinical practice and research settings.

Despite these promising findings, several limitations must be acknowledged. Considerable heterogeneity exists among studies with respect to MRI acquisition parameters, scanner field strengths, image processing techniques, and region-of-interest definitions. Variability in patient populations, disease phenotypes, and treatment status further complicates direct comparison of findings. Additionally, many studies are cross-sectional, limiting conclusions regarding causality and long-term prognostic value. Publication bias and selective reporting may also influence the available literature.

Future research should prioritize multicenter longitudinal studies employing standardized imaging protocols and harmonized analytical methods. Integration of advanced MRI metrics with clinical, immunological, genetic, and fluid biomarkers may provide a more comprehensive understanding of disease mechanisms. The application of machine learning and artificial intelligence to multimodal imaging datasets may further improve prediction of disease progression and individualized treatment strategies.

In summary, advanced MRI techniques represent a major advancement in the evaluation of multiple sclerosis. By capturing pathological processes that are not visible on conventional imaging, these modalities offer valuable biomarkers of disease progression and disability. Continued methodological refinement and validation will be essential for translating these promising tools into routine clinical practice and future therapeutic trials, 

Advanced MRI techniques have significantly expanded understanding of multiple sclerosis pathology. MTI, DTI, MRS, QSM, and fMRI provide complementary information regarding tissue integrity, neurodegeneration, iron deposition, and functional reorganization. Evidence indicates that these modalities correlate more closely with disability progression than conventional lesion-based measures. Future research should focus on protocol harmonization, longitudinal validation, and integration of multimodal imaging biomarkers into clinical practice.

1. Filippi M, Bar‑Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.
2. York EN, Thrippleton MJ, Meijboom R, Hunt DPJ, Waldman AD. Quantitative magnetization transfer imaging in relapsing‑remitting multiple sclerosis: a systematic review and meta‑analysis. Brain Commun. 2022;4(2):fcac088.
3. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15(3):292–303.
4. Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, et al. MAGNIMS‑CMSC‑NAIMS consensus recommendations on the use of MRI in multiple sclerosis. Lancet Neurol. 2015;14(8):807–817.
5. Barkhof F. The clinico‑radiological paradox in multiple sclerosis revisited. Curr Opin Neurol. 2002;15(3):239–245.
6. Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019;142(7):1858–1875.
7. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56(3):407–415.
8. Ge Y, Grossman RI, Udupa JK, Babb JS, Kolson DL, McGowan JC. Magnetization transfer ratio histogram analysis of gray matter in relapsing‑remitting multiple sclerosis. AJNR Am J Neuroradiol. 2001;22(3):470–476.
9. Vrenken H, Pouwels PJW, Geurts JJG, Knol DL, Polman CH, Barkhof F, Castelijns JA. Altered diffusion tensor in multiple sclerosis normal‑appearing brain tissue. Cereb Cortex. 2006;16(11):1586–1591.
10. Ciccarelli O, Werring DJ, Wheeler‑Kingshott CAM, Barker GJ, Parker GJM, Thompson AJ, Miller DH. Investigation of MS normal‑appearing brain using diffusion tensor MRI. Neurology. 2001;56(7):926–932.
11. Filippi M, Iannucci G, Cercignani M, Rocca MA, Pratesi A, Comi G. A quantitative study of water diffusion in multiple sclerosis lesions and normal‑appearing white matter. Neurology. 2000;54(3):602–608.
12. Rocca MA, Agosta F, Mezzapesa DM, Falini A, Martinelli V, Comi G, Filippi M. Magnetization transfer and diffusion tensor MRI show gray matter damage in multiple sclerosis. Neurology. 2004;62(10):1736–1742.
13. Inglese M, Li BSY, Rusinek H, Babb JS, Grossman RI, Gonen O. Diffusely elevated cerebral choline and creatine in relapsing‑remitting multiple sclerosis. Magn Reson Med. 2003;50(1):190–195.
14. De Stefano N, Narayanan S, Francis GS, Smith S, Mortilla M, Tartaglia MC, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol. 2002;59(10):1565–1571.
15. Haacke EM, Miao Y, Liu M, Habib CA, Katkuri Y, Liu T, et al. Iron stores and cerebral veins in multiple sclerosis studied by susceptibility‑weighted imaging. Int Angiol. 2010;29(2):149–157.
16. Hagemeier J, Weinstock‑Guttman B, Heininen‑Brown M, Poloni GU, Bergsland N, Schirda C, et al. Gray matter SWI‑filtered phase and cognition in multiple sclerosis. Mult Scler. 2013;19(10):1312–1319.
17. Zhang Y, Gauthier SA, Gupta A, Comunale J, Chiang GC, Zhou D, et al. Quantitative susceptibility mapping and R2* measured changes during relapsing‑remitting multiple sclerosis. AJNR Am J Neuroradiol. 2016;37(3):426–432.
18. Rocca MA, Valsasina P, Absinta M, Riccitelli G, Rodegher M, Misci P, et al. Default‑mode network dysfunction and cognitive impairment in progressive multiple sclerosis. Neurology. 2010;74(16):1252–1259.
19. Faivre A, Rico A, Zaaraoui W, Crespy L, Reuter F, Wybrecht D, et al. Assessing brain connectivity at rest in patients with multiple sclerosis. Radiology. 2012;263(2):528–537.
20. Filippi M, Rocca MA. Functional MR imaging in multiple sclerosis. Neuroimaging Clin N Am. 2009;19(1):59–70.